Question 1

What is Inhibikase Therapeutics?

Accepted Answer

Inhibikase Therapeutics is a Company.

Question 2

How often does Inhibikase Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 8 articles.

Question 3

When was Inhibikase Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on Apr 03, 2026.

Question 4

When was Inhibikase Therapeutics last mentioned in news?

Accepted Answer

Last active on Jul 02, 2026.

Question 5

What is Inhibikase Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Inhibikase Therapeutics in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Inhibikase Therapeutics?

Accepted Answer

Inhibikase Therapeutics Grants Stock Options (Apr 03, 2026, 8 articles).

Question 8

How did the "Inhibikase Therapeutics Grants Stock Options" event impact Inhibikase Therapeutics?

Accepted Answer

Inhibikase Therapeutics granted stock options to new employees as an inducement for employment, which is a common practice to attract talent and align employee interests with shareholder value. This action could positively impact the company's ability to retain and motivate its workforce.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.